JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273169

HRP Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Mouse IgG1 (Chimeric)

Be the first to review this product! Submit a review

|

(2 Publications)

Mouse Recombinant Monoclonal SPIKE antibody - conjugated to HRP. Suitable for ELISA and reacts with Recombinant fragment - SARS-CoV-2 samples. Cited in 2 publications.
1 Images
ELISA - HRP Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Mouse IgG1 (Chimeric) (AB273169)
  • ELISA

Supplier Data

ELISA - HRP Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Mouse IgG1 (Chimeric) (AB273169)

The binding activity of ab273169 with SARS-CoV-2 spike glycoprotein protein.

Measured by its binding activity in a functional ELISA. Immobilized SARS-CoV-2 spike glycoprotein at 2 μg/ml can bind ab273169 with an IC50 of 298.5 to 368.1 ng/ml.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

H6

Isotype

IgG1

Conjugation

HRP

Excitation/Emission
Carrier free

No

Reacts with

SARS-CoV-2

Applications

ELISA

applications

style
left-column

Complementary Products

Assay Kits

AB284402

COVID-19 S-Protein (S1RBD) ELISA Kit

ELISA - COVID-19 S-Protein (S1RBD) ELISA Kit (AB284402)

  • 0
  • 0
Secondary Antibodies

AB150113

Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) (AB150113)

  • 5
  • 16
Primary Antibodies

AB316283

Anti-Hepatitis B Virus Core Antigen antibody [EPR28251-34]

BOND RX™ Validated|20ul selling size|Recombinant|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Hepatitis B Virus Core Antigen antibody [EPR28251-34] (AB316283)

  • 5
  • 1
Proteins & Peptides

AB193473

Recombinant Hepatitis B virus Hepatitis B Surface Antigen AD protein

  • 0
  • 0
Primary Antibodies

AB8635

Anti-Hepatitis B Virus pre S2 Antigen antibody [S26]

Western blot - Anti-Hepatitis B Virus pre S2 Antigen antibody [S26] (AB8635)

  • 4
  • 2
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Recombinant fragment - SARS-CoV-2": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "<p></p>" }, "SARS-CoV-2": { "ELISA-species-checked": "predicted", "ELISA-species-dilution-info": "", "ELISA-species-notes": "" } } }
style
left-column

Product details

Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Chimeric (ab272854) is a recombinant human/mouse chimeric monoclonal antibody consisting of Mouse scFv fused with human IgG1.

As the Fc region is human, an anti-Human secondary antibody should be used for detection.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Storage buffer
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.
Biological function summary

The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.

Pathways

The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.

The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

See full target information SARS-CoV-2 spike glycoprotein
style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 13:837443 PubMed35281065

2022

A Thermostable Oral SARS-CoV-2 Vaccine Induces Mucosal and Protective Immunity.

Applications

Unspecified application

Species

Unspecified reactive species

Bertrand Bellier,Alicia Saura,Lucas A Luján,Cecilia R Molina,Hugo D Luján,David Klatzmann

Vaccines 9: PubMed33925446

2021

A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.

Applications

Unspecified application

Species

Unspecified reactive species

Duško Lainšček,Tina Fink,Vida Forstnerič,Iva Hafner-Bratkovič,Sara Orehek,Žiga Strmšek,Mateja Manček-Keber,Peter Pečan,Hana Esih,Špela Malenšek,Jana Aupič,Petra Dekleva,Tjaša Plaper,Sara Vidmar,Lucija Kadunc,Mojca Benčina,Neža Omersa,Gregor Anderluh,Florence Pojer,Kelvin Lau,David Hacker,Bruno E Correia,David Peterhoff,Ralf Wagner,Valter Bergant,Alexander Herrmann,Andreas Pichlmair,Roman Jerala
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com